E
Senti Biosciences, Inc. SNTI
$1.65 $0.0553.46% NASDAQ
Recommendation
Prev Close
$1.65
Volume
70,307
Avg Vol (90D)
272,401
Market Cap
$43.03M
Dividend & Yield
--
52-Week Range
$1.46 - $16.94
P/E (TTM)
--
EPS (TTM)
-$9.62
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025
8/15/2025 - ACCESS Newswire
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: ...
8/14/2025 - GuruFocus
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: ...
8/14/2025 - GuruFocus
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
8/14/2025 - Globe Newswire
Senti Bio Participates in Virtual Investor What This Means Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia
8/12/2025 - Globe Newswire
Senti Biosciences Inc Reports Q2 2025 Earnings: EPS at -$0. ...
8/9/2025 - GuruFocus
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025
8/7/2025 - Globe Newswire
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia
8/5/2025 - Globe Newswire
Senti Biosciences (NASDAQ:SNTI) Trading 3.6% Higher - Should You Buy?
8/5/2025 - Ticker Report
Senti Biosciences Participates in the Virtual Investor What's Your Story Summer Spotlight On-Demand Conference
7/22/2025 - Globe Newswire
JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live
7/22/2025 - ACCESS Newswire
Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum
7/21/2025 - Globe Newswire
JTC Team Announces Participating Line Up for the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference
7/18/2025 - ACCESS Newswire
Senti Biosciences Appoints Bryan Baum to Board
7/18/2025 - TipRanks Financial Blog
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors
7/18/2025 - Globe Newswire
Senti Biosciences (NASDAQ:SNTI) Rating Increased to Sell at Wall Street Zen
7/13/2025 - Ticker Report
Senti Biosciences (NASDAQ:SNTI) Upgraded by Wall Street Zen to "Sell" Rating
7/12/2025 - MarketBeat
Senti Biosciences (NASDAQ:SNTI) Trading Up 2.5% - Here's What Happened
7/4/2025 - MarketBeat
Senti Bio Participates in Nasdaq Amplify Spotlight Series
6/30/2025 - Globe Newswire
Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference
6/24/2025 - Globe Newswire
Senti Biosciences (SNTI) Receives Orphan Drug Designation for SENTI-202 SNTI Stock News
6/18/2025 - GuruFocus
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
6/18/2025 - Globe Newswire
Senti Biosciences (SNTI) Rating and Price Target Updated by Chardan Capital SNTI Stock News
6/12/2025 - GuruFocus
Senti Biosciences (SNTI, $3.12) price exceeded its 50-day Moving Average on June 09, 2025
6/10/2025 - Tickeron - Stocks
Senti Biosciences Announces New Employment Inducement Grants SNTI Stock News
6/9/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$53.45M
EBIT (TTM)
-$57.18M
Net Income (TTM)
-$58.32M
Balance Sheet
Total Assets (Q)
$68.54M
Total Debt (Q)
$31.31M
Total Liabilities (Q)
$43.89M
Book Value Per Share (Q)
$0.9423
Cash Flow
Cash from Operations (TTM)
-$48.49M
Cash from Investing (TTM)
-$135.00K
Cash from Financing (TTM)
$54.33M
Net Change in Cash (TTM)
$5.70M
Filings
Filing Date
Thursday, August 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Loading...
Beta
1.09
7-Day Total Return
7.52%
30-Day Total Return
-16.50%
60-Day Total Return
-47.11%
90-Day Total Return
-55.18%
Year to Date Total Return
-56.82%
1-Year Total Return
-43.08%
2-Year Total Return
-74.30%
3-Year Total Return
-91.78%
5-Year Total Return
--
52-week Low
Aug 12, 2025 - $1.46
52-week High
Dec 02, 2024 - $16.94
Valuation
Market Cap
$43.03M - Nano Cap
Enterprise Value
$52.67M
Price/Sales (TTM)
--
Price/Book (Q)
1.75
Dividends and Shares
Shares Outstanding
26.08
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.sentibio.com
Phone Number
650 239 2030
Address
2 Corporate Drive
South San Francisco, CA 94080
Country
United States
Year Founded
2016
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable... more
NASDAQ 08/22/2025 4:00PM Eastern Quotes delayed